This video is part of a three-part series covering new literature that could influence
clinical practice. In this video, I discuss the combined usage of antiplatelets with DOACs
in patients with ASCVD risk and atrial fibrillation. Each mechanism of action is reviewed,
as well as current indications for combination therapy. Background studies describe
risks of concurrent usage, as well as unprescribed usage of aspirin. Lastly, the EPIC-
CAD trial is summarized with its major findings and discussion about the potential to
influence practice.

This video was created by Emma Carlberg, PharmD Candidate.

Did you enjoy this blog post? Subscribers are emailed new blog posts TWICE per week! In addition, you’ll get access to the free giveaways below. Over 6,000 healthcare professionals have subscribed for our FREE Giveaways. Why haven’t you?!

• 30 medication mistakes PDF
• 18+ Page Drug Interaction PDF
• 10 Commandments of Polypharmacy Webinar based on my experiences in clinical practice